These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 9426745)

  • 1. Proposed substages for metastatic prostate cancer.
    Crawford ED; Blumenstein BA
    Urology; 1997 Dec; 50(6):1027-8. PubMed ID: 9426745
    [No Abstract]   [Full Text] [Related]  

  • 2. Proposed update on substaging metastatic prostate cancer.
    Crawford ED; Connor T
    Urology; 2009 Jul; 74(1):237. PubMed ID: 19567307
    [No Abstract]   [Full Text] [Related]  

  • 3. [How to treat locally advanced and metastatic untreated cancer of the prostate?].
    Khoury S
    Prog Urol; 1996 Apr; 6(2 Suppl 1):42-5. PubMed ID: 8704744
    [No Abstract]   [Full Text] [Related]  

  • 4. [Metastatic prostate carcinoma].
    Smith MR; Kantoff P; Talcott J
    Praxis (Bern 1994); 2001 Sep; 90(38):1653-8. PubMed ID: 11675919
    [No Abstract]   [Full Text] [Related]  

  • 5. [Cancer of the prostate: reclaiming Gleason's sum].
    Espuela Orgaz R; Nogueras Gimeno MA; Passas Martínez J; Ruiz Liso JM; Sanz Anquela M
    Actas Urol Esp; 1982; 6(6):317-22. PubMed ID: 7183177
    [No Abstract]   [Full Text] [Related]  

  • 6. Elevated serum progastrin-releasing peptide (31-98) level is a predictor of short response duration after hormonal therapy in metastatic prostate cancer.
    Yashi M; Nukui A; Kurokawa S; Ochi M; Ishikawa S; Goto K; Kobayashi Y; Muraishi O; Tokue A
    Prostate; 2003 Sep; 56(4):305-12. PubMed ID: 12858359
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Presence of prostate cancer metastasis correlates with lower lymph node reactivity.
    Gannon PO; Alam Fahmy M; Bégin LR; Djoukhadjian A; Filali-Mouhim A; Lapointe R; Mes-Masson AM; Saad F
    Prostate; 2006 Dec; 66(16):1710-20. PubMed ID: 16955408
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Utilizing the tumor-node-metastasis staging for prostate cancer: the sixth edition, 2002.
    Chang SS; Amin MB
    CA Cancer J Clin; 2008; 58(1):54-9. PubMed ID: 18096866
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metastatic prostate cancer-does treatment of the primary tumor matter?
    Swanson G; Thompson I; Basler J; Crawford ED
    J Urol; 2006 Oct; 176(4 Pt 1):1292-8. PubMed ID: 16952615
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Amphoterin induction in prostatic stromal cells by androgen deprivation is associated with metastatic prostate cancer.
    Kuniyasu H; Chihara Y; Kondo H; Ohmori H; Ukai R
    Oncol Rep; 2003; 10(6):1863-8. PubMed ID: 14534709
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The prognostic role of the pathological T2 subclassification for prostate cancer in the 2002 Tumour-Nodes-Metastasis staging system.
    van Oort IM; Witjes JA; Kok DE; Kiemeney LA; Hulsbergen-Van De Kaa CA
    BJU Int; 2008 Aug; 102(4):438-41. PubMed ID: 18336608
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjuvant radiotherapy after surgery for pathologically advanced prostate cancer.
    Van der Kwast TH; Collette L; Bolla M
    J Clin Oncol; 2007 Dec; 25(35):5671-2. PubMed ID: 18065746
    [No Abstract]   [Full Text] [Related]  

  • 13. Secondary cancer and relapse rates following radical prostatectomy for prostate-confined cancer.
    Wesley D; Cox HF
    J Insur Med; 2007; 39(4):242-50. PubMed ID: 18522141
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The natural history of metastatic prostate cancer].
    Lebret T; Méjean A
    Prog Urol; 2008 Nov; 18 Suppl 7():S327-31. PubMed ID: 19070811
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunomagnetic quantification of circulating tumor cells as a prognostic factor of androgen deprivation responsiveness in patients with hormone naive metastatic prostate cancer.
    Okegawa T; Nutahara K; Higashihara E
    J Urol; 2008 Oct; 180(4):1342-7. PubMed ID: 18707699
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Diagnosis and treatment of prostate cancer].
    Auvert J
    Ann Urol (Paris); 1999; 33(4):259-62. PubMed ID: 10510707
    [No Abstract]   [Full Text] [Related]  

  • 17. Metastatic disease of screen-detected prostate cancer : characteristics at diagnosis.
    Roemeling S; Kranse R; Vis AN; Gosselaar C; van der Kwast TH; Schröder FH
    Cancer; 2006 Dec; 107(12):2779-85. PubMed ID: 17109445
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of P501S and PSA in the diagnosis of metastatic adenocarcinoma of the prostate.
    Sheridan T; Herawi M; Epstein JI; Illei PB
    Am J Surg Pathol; 2007 Sep; 31(9):1351-5. PubMed ID: 17721190
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evolving treatment paradigms for locally advanced and metastatic prostate cancer.
    Dorff TB; Quek ML; Daneshmand S; Pinski J
    Expert Rev Anticancer Ther; 2006 Nov; 6(11):1639-51. PubMed ID: 17134367
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative assessment of the 1992 and 2002 pathologic T3 substages for the prediction of biochemical recurrence after radical prostatectomy.
    Steuber T; Erbersdobler A; Graefen M; Haese A; Huland H; Karakiewicz PI
    Cancer; 2006 Feb; 106(4):775-82. PubMed ID: 16400637
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.